CTLA4 and metastatic melanoma: Following the approval of ipilimumab (anti-CTLA-4) by FDA to treat metastatic melanoma in 2011, 5 more checkpoint blockade therapies have emerged, all of which target the PD-1/PD-L1 axis and are used for treating several tumor types.